Last reviewed · How we verify

Etanercept + Acitretin — Competitive Intelligence Brief

Etanercept + Acitretin (Etanercept + Acitretin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TNF inhibitor + retinoid combination. Area: Dermatology / Immunology.

marketed TNF inhibitor + retinoid combination TNF-α receptor (p75/p55) + retinoid X receptor (RXR) and retinoic acid receptor (RAR) Dermatology / Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Etanercept + Acitretin (Etanercept + Acitretin) — Pfizer. Etanercept blocks TNF-α signaling while acitretin normalizes keratinocyte differentiation and reduces inflammation, together targeting both immune and skin-barrier dysfunction in psoriasis.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Etanercept + Acitretin TARGET Etanercept + Acitretin Pfizer marketed TNF inhibitor + retinoid combination TNF-α receptor (p75/p55) + retinoid X receptor (RXR) and retinoic acid receptor (RAR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TNF inhibitor + retinoid combination class)

  1. Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Etanercept + Acitretin — Competitive Intelligence Brief. https://druglandscape.com/ci/etanercept-acitretin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: